spacer
The Healthcare Sales & Marketing Network celebrates 26 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  lenalidomide 

 HSMN NewsFeed - 14 Jun 2024
TALVEY(R) (talquetamab-tgvs) Demonstrates Highly Durable, Longer-Term Responses in Patients with Relapsed or Refractory Multiple Myeloma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 12 Jul 2021
Janssen Announces U.S. FDA Approval of DARZALEX FASPRO(R) (daratumumab and hyaluronidase-fihj) in Combination with Pomalidomide and Dexamethasone for Patients with Multiple Myeloma After First or Subsequent Relapse
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 13 Apr 2020
Antengene Corporation Appoints Former Celgene ANZ General Manager Thomas Karalis as Head of Asia Pacific Regions
Biopharmaceuticals Personnel
 HSMN NewsFeed - 3 Jan 2020
Leap Therapeutics and BeiGene Announce Exclusive Option and License Agreement for DKN-01 and Leap Announces $27 Million Equity Financing
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 15 Oct 2019
World Renowned Experts Appointed to Skyhawk Therapeutics Scientific Advisory Board
Biopharmaceuticals Personnel
 HSMN NewsFeed - 12 Feb 2019
U.S. FDA Approves DARZALEX(R) (daratumumab) Split-Dosing Regimen
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 1 Oct 2018
FDA Approves KYPROLIS(R) (carfilzomib) Once-Weekly 70 mg/m2 In Combination With Dexamethasone (Kd70) For Patients With Relapsed Or Refractory Multiple Myeloma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 5 Sep 2018
Compugen Announces Appointment of Dr. Jean-Pierre Bizzari to its Board of Directors
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 8 Aug 2018
Janssen Submits U.S. & EU Regulatory Applications Seeking Approval of DARZALEX(R) (daratumumab) Split Dosing Regimen
Biopharmaceuticals Oncology FDA Regulatory
 HSMN NewsFeed - 12 Dec 2017
DARZALEX(R) (daratumumab) Combination Regimen Significantly Improved Outcomes for Newly Diagnosed Multiple Myeloma Patients who are Transplant Ineligible
Biopharmaceuticals Oncology
 HSMN NewsFeed - 16 Mar 2017
Oncolytics Biotech(R) Inc. Enters into First-in-Class Collaboration with Myeloma UK and Celgene Using REOLYSIN(R) in Combination with Imnovid(R) or Revlimid(R) in Patients with Myeloma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 24 Feb 2017
CHMP Issues Positive Opinion Recommending DARZALEX(R) (daratumumab) for Relapsed or Refractory Multiple Myeloma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 28 Nov 2016
Conditional Approval from the European Commission to Treat Multiple Myeloma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 22 Nov 2016
DARZALEX(R) (daratumumab) Approved by U.S. FDA in Combination with Two Standard of Care Regimens for the Treatment of Patients with Multiple Myeloma Who Have Received At Least One Prior Therapy
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 8 Aug 2016
Takeda Receives Marketing Authorization in Canada for NINLARO(TM) (ixazomib) in Relapsed/Refractory Multiple Myeloma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 15 Jul 2016
REVLIMID(R) (Lenalidomide) Approved by the European Commission for the Treatment of Relapsed/Refractory Patients with Mantle Cell Lymphoma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 4 Jul 2016
European Commission Approves Extended Indication For Amgen's Kyprolis(R) (Carfilzomib) For The Treatment Of Relapsed Multiple Myeloma Patients
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 21 Dec 2015
Oral REVLIMID(R) Plus Dexamethasone Granted Approval for Treatment of Patients with Newly Diagnosed Multiple Myeloma in Japan
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 27 Jul 2015
European Medicines Agency Validates and Grants Accelerated Assessment of Marketing Authorization Application for Empliciti (elotuzumab) For the Treatment of Multiple Myeloma in Patients Who Have Received One or More Prior Therapies
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 20 Feb 2015
REVLIMID(R) (Lenalidomide) Approved by the European Commission for the Treatment of Adult Patients with Previously Untreated Multiple Myeloma who are Not Eligible for Transplant
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 5 Mar 2014
Genmab Announces Phase III Study of Daratumumab in Relapsed or Refractory Multiple Myeloma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 18 Jul 2013
Celgene Will Discontinue Phase III ORIGIN(R) Trial in Previously Untreated Elderly Patients with B-Cell Chronic Lymphocytic Leukemia
Biopharmaceuticals Oncology
 HSMN NewsFeed - 31 May 2013
Oral Anti-Cancer Therapy Pomalidomide Celgene Receives Positive CHMP Opinion as Treatment for Patients with Relapsed and Refractory Multiple Myeloma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 21 Feb 2013
ARIAD Announces Appointment of European General Manager and Other Key Members of Leadership Team
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 29 Jan 2013
Bionor Pharma Appoints Anker Lundemose as President and Chief Executive Officer
Biopharmaceuticals HIV/AIDS Personnel
 HSMN NewsFeed - 22 Jan 2013
Clinical Trials Advancing Proton Therapy Research Open at the CDH Proton Center, A ProCure Center
Devices Oncology
 HSMN NewsFeed - 20 Jul 2012
Onyx Pharmaceuticals Receives FDA Accelerated Approval of Kyprolis(TM) (carfilzomib) for Injection
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 14 Mar 2011
Cell Therapeutics Acquires Exclusive Marketing and Co-Development Rights in the Americas to Chroma Therapeutics' Tosedostat, a First in Class Tumor Selective Oral Therapy for Treatment of Blood Related and Other Cancers
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 8 Sep 2010
Onyx Pharmaceuticals Announces Carfilzomib Development and Commercialization Agreement with Ono Pharmaceutical for Japan
Biopharmaceuticals Oncology
 HSMN NewsFeed - 20 Aug 2010
REVLIMID(R) Approved for Treatment of Deletion 5q Myelodysplastic Syndromes in Japan
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 13 Aug 2010
Human Genome Sciences Names Tuomo Pätsi Vice President, HGS Europe
Biopharmaceuticals Personnel
 HSMN NewsFeed - 12 Oct 2009
Proteolix, Inc. to be Acquired By Onyx Pharmaceuticals
Biopharmaceuticals Oncology Mergers & Acquisitions
 HSMN NewsFeed - 6 Oct 2008
Oral Cancer Drug REVLIMID(R) Receives Marketing Authorization from Health Canada for Treatment of Multiple Myeloma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 5 Sep 2008
Elan and Biogen Idec Initiate First Clinical Trial of TYSABRI(R) in Oncology
Biopharmaceuticals Oncology
 HSMN NewsFeed - 2 Jun 2008
Celgene Withdraws European Union (EU) Marketing Authorization Application for Lenalidomide in Deletion-5Q Myelodysplastic Syndromes
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 1 Jun 2008
Updated REVLIMID(R) Data Presented in Newly Diagnosed Multiple Myeloma Presented at the 2008 American Society of Clinical Oncology (ASCO) Meeting
Biopharmaceuticals Oncology
 HSMN NewsFeed - 19 Feb 2008
Lenalidomide (REVLIMID(R)) Receives Orphan Drug Status in Japan for Multiple Indications
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 24 Jan 2008
Celgene Reports on REVLIMID(R) (Lenalidomide) Global Regulatory Developments in Multiple Myeloma and Deletion 5Q Myelodysplastic Syndromes
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 9 Dec 2007
SWOG Phase III Trial Reports REVLIMID(R) (lenalidomide) Plus Dexamethasone Achieves Superior Progression-Free Survival in Newly Diagnosed Multiple Myeloma Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 9 Dec 2007
REVLIMID(R) (Lenalidomide) Plus Low-Dose Dexamethasone Achieves Unprecedented Survival Rate in ECOG Phase III Trial in Newly Diagnosed Multiple Myeloma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 30 Nov 2007
Lenalidomide (REVLIMID(R)) Receives Orphan Medicinal Product Designation from the European Commission for Chronic Lymphocytic Leukemia
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 12 Nov 2007
Cancer Drug REVLIMID(R) Receives Recommendation for Approval from Australian Drug Evaluation Committee for Treatment of Multiple Myeloma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 17 Sep 2007
Updated REVLIMID(R) Clinical Results Presented at the 12th International Workshop on Chronic Lymphocytic Leukemia
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Sep 2007
Oral Cancer Drug REVLIMID(R) Receives Swissmedic Approval in Switzerland for Treatment of Multiple Myeloma
Biopharmaceuticals Regulatory Oncology
 HSMN NewsFeed - 15 Aug 2007
Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 9 Aug 2007
Nereus Pharmaceuticals Raises $45 Million in Series D-2 Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 29 Jun 2007
Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstrom's Macroglobulinemia
Biopharmaceuticals Oncology
 HSMN NewsFeed - 28 Jun 2007
VELCADE(R) (Bortezomib) for Injection Based Therapies Produced Complete Remission Rates as High as 54 Percent in Patients With Previously Treated Multiple Myeloma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 28 Jun 2007
VELCADE(R) (Bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 19 Jun 2007
REVLIMID(R) Granted Full Marketing Authorization for Treatment of Multiple Myeloma in the European Union
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 15 May 2007
SWOG Phase III Newly Diagnosed Multiple Myeloma Trial (S0232) Closed and Patients Given Choice to Switch to REVLIMID(R) Plus Dexamethasone
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Apr 2007
ECOG Phase III Newly Diagnosed Multiple Myeloma Trial (E4A03) Reports LENALIDOMIDE Plus Low-Dose Dexamethasone Suggests Survival Advantage for Patients with Multiple Myeloma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 23 Mar 2007
Oral Cancer Drug REVLIMID(R) Receives Positive Opinion for Treatment of Multiple Myeloma From European Medicines Agency
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 8 Jan 2007
NCCN Updates Antiemesis Guidelines
Biopharmaceuticals Oncology
 HSMN NewsFeed - 28 Dec 2006
The Multiple Myeloma Research Consortium (MMRC) and Keryx Biopharmaceuticals Commence Multi-Center Combination Study for the Treatment of Multiple Myeloma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 11 Dec 2006
Positive Results from Combination Trials Build on VELCADE(R) (Bortezomib) for Injection Proven Single-Agent Strength in Relapsed Multiple Myeloma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 8 Dec 2006
49 Abstracts Evaluating Revlimid(R) To Be Presented at The 48th American Society of Hematology Meeting
Biopharmaceuticals Oncology
 HSMN NewsFeed - 2 Oct 2006
Updated REVLIMID(R) (lenalidomide) Clinical Results Presented at the 3rd International Conference on Innovative Therapies for Lymphoid Malignancies
Biopharmaceuticals Oncology
 HSMN NewsFeed - 29 Jun 2006
The International Myeloma Foundation Says REVLIMID(R) Approval for Multiple Myeloma Can Be Life-Changing for Cancer Patients
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 29 Jun 2006
REVLIMID(R) in Combination With Dexamethasone sNDA Granted Approval By FDA for Treatment of Multiple Myeloma
Biopharmaceuticals Oncology FDA
Return to NewsFeed  

 Additional items found! 25

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 25 additional stories matching:
lenalidomide
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.